RainDance Technologies has filed for an IPO, looking to raise up to $60 million. The company, which plans to list shares on the NASDAQ under the symbol RAIN, is developing genomic tools with non-invasive biopsy applications for research and early detection of cancer and other inherited and infectious diseases. RainDance's revenues grew nearly 80% to $30.6 million from 2013 to 2014, with net loss decreasing by $5.5 million. Its most recent VC funding came in February 2014, when it grabbed $42 million in a Series E round that valued the company at $132 million. Backers include Mohr Davidow Ventures (34.4% pre-IPO stake), Quaker BioVentures (18.5%) and Alloy Ventures (13.3%).